Advertisement

Fall 62: Therapie – 33 Jahre, ♀, DM Typ 2, schwanger, Übergewicht

  • Chrisitan Kasperk
Chapter

Zusammenfassung

Eine 33-jährige Typ-2-Diabetikerin mit einem Body-Mass-Index von 39, einem HbA1c von 9,5 %, schwanger seit 3 Monaten, wird mit einem Sulfonylharnstoff behandelt und besucht jetzt zum ersten Mal einen Diabetologen. Ist sie richtig therapiert?

Literatur

  1. Bergel R, Hadar E, Toledano Y, Hod M (2016) Pharmacological management of gestational diabetes mellitus. Curr Diab Rep 16:118–127CrossRefGoogle Scholar
  2. Brown J, Martis R, Hughes B, Rowan J, Crowther C (2017) Oral anti-diabetic pharmacological therapies for the treatment of women with gestational diabetes (review). Cochrane database of systematic reviews Issue 1, Art.nr. CD011967Google Scholar
  3. deJong J, Garne E, Wender E, Morgan M, Wang H (2016) Insulin analogues in pregnancy and specific congenital anomalies: a literature review. Diab Metab Res Rev 32:366–375CrossRefGoogle Scholar
  4. Ferrara A, Weiss N, Hedderson M, Quesenberry C, Selby J, Ergas I, Peng T, Escobar G, Pettitt D, Sacks D (2007) Pregnancy plasma glucose levels exceeding the American diabetes accosiation thresholds but below the national diabetes data group thresholds for gestational diabetes mellitus, are leated to the risk of neonatal macrosomia, hypoglycemia and hyperbilirubinemia. Diabetologia 50:298–306CrossRefGoogle Scholar
  5. HAPO Study Cooperative Research Group (2002) The hyperglycemia and adverse pregnancy outcome study. Int J Gynecol Obstet 1:69–77CrossRefGoogle Scholar
  6. International Association of diabetes and pregnancy study groups consensus panel (2010) International association of diabetes and pregnancy study group recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 33:676–682CrossRefGoogle Scholar
  7. Langer O, Conway D, Berkus M, Xenakis E, Gonzales O (2000) A comparison of glyburide and insulin in women with gestational diabetes mellitus. New Engl J Med 343:1143–1148CrossRefGoogle Scholar
  8. Lv S, Wang J, Xu Y (2015) Safety of insulin analogs during pregnancy: a meta analysis. Arch Gynecol Ostet 292:749–756CrossRefGoogle Scholar
  9. Magee L, von Dadelszen P, Rey E, Ross S et al (2015) Less tight versus tight control of hypertension in pregnancy. New Engl J Med 372:407–417CrossRefGoogle Scholar
  10. Mills J, Simpson J, Driscoll S, Jovanovic-Peterson L et al (1988) Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. N Engl J Med 319:1617–1623CrossRefGoogle Scholar
  11. Piacquadio K, Hollingsworth D, Murphy H (1991) Effects of in utero exposure to oral hypoglycaemic drugs. Lancet 338:866–869CrossRefGoogle Scholar
  12. Rowan J, Hague W, Gao W, Battin M, Moore M (2008) Metformin verus insulin for the treatment of gestational diabetes. N Engl J Med 358:2003–2015CrossRefGoogle Scholar
  13. Towner D, Kjos S, Leung B, Montoro M, Xiang J, Buchanan T (1995) Congenital malformations in pregnancies complicated by NIDDM. Diabetes Care 18:1556–1451CrossRefGoogle Scholar
  14. Zucker P, Simon G (1968) Prolonged symptomatic neonatal hypoglycemia associated with maternal chlorpropamide therapy. Pediatrics 42:824–825PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Abteilung Innere Medizin IMedizinische UniversitätsklinikHeidelbergDeutschland

Personalised recommendations